Catalyst Wire Dossier Catalyst Wire Dossier

PRAME-immunotherapy (investigational)

· GlaxoSmithKline
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for PRAME-immunotherapy (investigational), covering 2019-08-28 to 2019-08-28. Get the full timeline:

Most recent: Clinical Trial Update: A Study to Demonstrate the Benefit of a New Kind of Anti-cancer Treatment [PReferentially Expressed Antigen of MElanoma (PRAME) Immunotherapy] for Patients With Non-Small Cell Lung Cancer (NSCLC), After Removal of Their Tumor [Phase 2]

See pricing